• Patient must be ≥ 12 years of age.

• Patient must have an ECOG performance status of 0-2 or KPS ≥ 60.

• Patient must have an expected survival of at least three months.

• Patient must be willing to provide blood sample for pharmacokinetic study (to assess proper administration of NEO100).

⁃ Patient must have adequate organ and marrow function as defined below:

⁃ White blood cell (WBC) ≥2000/microliter

⁃ Absolute neutrophil count (ANC) ≥ 1,500/microliter

⁃ Platelets ≥ 100,000/microliter

⁃ Hemoglobin ≥9 gm/dl

⁃ AST (SGOT)/ALT (SPGT) ≤ 2.5 × laboratory upper limit of normal (ULN)

⁃ Serum creatinine ≤ 1.5 x laboratory upper limit of normal (ULN) or

⁃ Creatinine clearance (meas or calc) ≥60mL/min for participants with creatinine levels \>1.5x laboratory upper limit of normal (ULN)

⁃ Total serum bilirubin ≤ 1.5 x laboratory upper limit of normal (ULN) except participants with Gilbert's Syndrome who can have a total serum bilirubin of \<5 x laboratory upper limit of normal (ULN)

⁃ MRI (or CT if MRI contraindicated) within 14 days prior to start of study drug. Corticosteroid dose must be stable or decreasing for at least 5 days prior to the scan. If steroids are added or the steroid dose is increased between the date of the screening scan and the start of treatment, a new baseline scan is required.

⁃ Female patients of child-bearing potential and male patients must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for 30 days prior to the first administration of study drug, for the duration of study participation, and for 90 days following completion of therapy. Should a female patient become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

⁃ A female of child-bearing potential is any woman (regardless of sexual orientation, not having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

⁃ i. Has not undergone a hysterectomy or bilateral oophorectomy; or ii. Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).

⁃ A negative serum pregnancy test will be required of all female patients of child-bearing potential within seven days prior to initiating study drug.

⁃ A serum pregnancy test will be repeated immediately if pregnancy is suspected.

⁃ Women must not be breastfeeding.

⁃ Patient must have the ability to understand, and the willingness comply with scheduled visits, treatment schedule, laboratory testing and other requirements of the study as confirmed by signing a written informed consent document.